RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases